Compounds > norfloxacin nicotinate
Page last updated: 2024-12-07

norfloxacin nicotinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norfloxacin nicotinate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID83908
SCHEMBL ID4864800
MeSH IDM0237564

Synonyms (28)

Synonym
norfloxacin nicotinate
3-quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, mono-3-pyridinecarboxylate
3-quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-, mono-3-pyridinecarboxylate
D08287
quinabic soluble powder (tn) [veterinary]
118803-81-9
c22h23fn4o5
FT-0631092
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound with nicotinic acid (1:1)
SCHEMBL4864800
nicotinic acid norfloxacin
WRIFLTAYLRDENF-UHFFFAOYSA-N
DTXSID10152246
J-003889
AKOS027322041
E76213
mfcd00873666
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;pyridine-3-carboxylic acid
DS-11847
BCP13348
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid nicotinic acid salt
A910803
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid nicotinate
CS-0144754
norfloxacin (nicotinate)
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylicacidcompoundwithnicotinicacid(1:1)
HY-B0132B
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; pyridine-3-carboxylic acid

Research Excerpts

Overview

Norfloxacin nicotinate (NFN) is a new water-soluble fluoroquinolone antibacterial agent.

ExcerptReferenceRelevance
"Norfloxacin nicotinate (NFN) is a new water-soluble fluoroquinolone antibacterial agent. "( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration.
Shem-Tov, M; Ziv, G, 1994)		1.99

Toxicity

ExcerptReferenceRelevance
" Nowadays, increasing evidences showed that NOR could pose toxic effects on fish and other aquatic organisms, but as its adduct, whether NOR-N could cause adverse effects on aquatic organisms is still unclear."( Effects of norfloxacin nicotinate on the early life stage of zebrafish (Danio rerio): Developmental toxicity, oxidative stress and immunotoxicity.
Fang, H; Li, K; Liang, X; Nie, X; Wang, F, 2020)		0.95

Pharmacokinetics

ExcerptReferenceRelevance
" The in vitro activity of NFN for microorganisms isolated from swine and the pharmacokinetic properties of NFN following single intravenous (i."( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration.
Shem-Tov, M; Ziv, G, 1994)		0.55
" However, a significant difference was observed in clearance, mean residence time and the half-life values between the unweaned and weaned calves."( Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves.
Gips, M; Soback, S, 1996)		1.74
" The pharmacokinetic parameters of common carp were similar to those of crucian carp."( Comparative pharmacokinetics of norfloxacin nicotinate in common carp (Cyprinus carpio) and crucian carp (Carassius auratus) after oral administration.
Ai, X; Liu, Y; Xu, N; Yang, Q, 2015)		0.7

Bioavailability

ExcerptReferenceRelevance
" Oral bioavailability was rather poor (9."( Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys.
Glickman, A; Lavy, E; Ziv, G, 1995)		0.51
" Bioavailability was 51-64%."( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration.
Shem-Tov, M; Ziv, G, 1994)		0.55
" The absorption rate after intramuscular administration appeared to change as a result of dose increase."( Norfloxacin nicotinate pharmacokinetics in unweaned and weaned calves.
Gips, M; Soback, S, 1996)		1.74

Dosage Studied

ExcerptRelevanceReference
" After multiple dosing some local swelling was observed at the injection site."( Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys.
Glickman, A; Lavy, E; Ziv, G, 1995)		0.51
" dosing best fitted a 2-compartment open system pharmacokinetic model."( Clinical pharmacokinetic characterization of norfloxacin nicotinate in swine following systemic administration.
Shem-Tov, M; Ziv, G, 1994)		0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (77.78)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.81 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index1.00 (0.95)

This Compound (25.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (11.11%)4.05%
Observational0 (0.00%)0.25%
Other7 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		591fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.3811monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
enrofloxacin
Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.		3.3811cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
ConditionIndicatedRelationship StrengthStudiesTrials
Bovine Diseases
[description not available]		01.9810
Genital Diseases, Male
Pathological processes involving the male reproductive tract (GENITALIA, MALE).		01.9810
Infections, Pseudomonas
[description not available]		01.9810
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		01.9810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.3811
Chronic Illness
[description not available]		03.3811
E coli Infections
[description not available]		03.3811
Eperythrozoonosis
[description not available]		03.3811
Poultry Diseases
Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.		03.3811
Infections, Respiratory
[description not available]		03.3811
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.3811
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		03.3811
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		03.3811